000			02047cam a2200205 4500500
005			20250112021355.0
041			_afre
042			_adc
100	1	0	_aGhariani, Inès _eauthor
700	1	0	_a Mahmoud, Oumaima _eauthor
700	1	0	_a Hamzaoui, Saloua _eauthor
700	1	0	_a Braham, Néjia Jmili _eauthor
700	1	0	_a Bekir, Leila _eauthor
245	0	0	_aHematological hypereosinophilia
260			_c2022.
500			_a78
520			_aIntroduction: Hematological disorders are the third-largest cause of hypereosinophilia, after allergic and parasitic disease. Objective: The objective of our study is to show the epidemiological, clinical, biological, and therapeutic characteristics of hematological hypereosinophilia. Patients and methods: This is a retrospective study conducted over a 4-year period (March 2017–March 2021) with 14 patients with hematological hypereosinophilia. Results: Fourteen patients were included (9 women and 5 men). The median age at diagnosis was 55 years. Hematological hypereosinophilia was mainly of clonal etiology. Clinical manifestations were either specific to hypereosinophilia, such as organ damage, or related to the etiology of hypereosinophilia, such as hepatosplenomegaly and lymphadenopathy. Moderate and severe forms were the most commonly reported. Several other quantitative and qualitative abnormalities of the blood picture were reported. Identification of the FIP1L1-PDGFRA fusion gene using molecular biology (RT-PCR) was positive in two patients. Imatinib was the main treatment for clonal forms. Conclusion: Hematological hypereosinophilia is a rare and complex pathology. Our study has confirmed this epidemiological, clinical, biological, and therapeutic heterogeneity and has enabled us to show the contribution of molecular biology in the diagnosis and treatment of hypereosinophilia.
786	0		_nAnnales de Biologie Clinique | 80 | 4 | 2022-07-01 | p. 355-362 | 0003-3898
856	4	1	_uhttps://shs.cairn.info/journal-annales-de-biologie-clinique-2022-4-page-355?lang=en
999			_c135674 _d135674